← Back to Search

111In-DAC Imaging for Breast Cancer

Phase 1

Waitlist Available

Research Sponsored by Copharos

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Being evaluated for a known or suspected breast tumor (must present with either a mammographic abnormality 10mm or larger or a mammographically occult but palpable abnormality of the breast)

Non-pregnant, non-lactating females 18 years of age or older (must agree to use an appropriate and effective method of birth control during the study and for 2 weeks after study)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new imaging tool to see if it can detect breast cancer.

Who is the study for?

This trial is for non-pregnant women over 18 with suspected or known breast tumors, scheduled for a biopsy. They must not be breastfeeding, agree to birth control during the study and two weeks after, and have signed consent. Excluded are those in recent trials, had certain biopsies or indium agents recently, have serious health issues including kidney/liver problems or severe allergies to trial drugs.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of a medical imaging agent called 111In-DAC used alongside planar and SPECT imaging techniques to detect breast cancer in patients who are already scheduled for tumor biopsy or surgery.See study design

What are the potential side effects?

Potential side effects may include allergic reactions to components of the imaging agent (111In-DAC), which could range from mild allergy symptoms to more severe anaphylaxis. Kidney damage is also a concern if there's prior susceptibility.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am being checked for a breast tumor, visible on mammogram or felt by touch.

Select...

I am a woman over 18, not pregnant or breastfeeding, and will use birth control during and after the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

CopharosLead Sponsor

1 Previous Clinical Trials

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00040430 — Phase 1

Breast Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00040430 — Phase 1

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00040430 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risks have been associated with this treatment protocol?

"As this is an early-stage trial, with minimal data supporting its efficacy and safety, the treatment has been assigned a score of 1."

Answered by AI

Does this clinical trial have any age restrictions, particularly for younger participants?

"This clinical trial seeks participants between ages 18 and 65. However, there are 74 trials designed for those under the age of majority and 2505 specifically targeting senior citizens."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer

2024. "Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00040430.

All > Aging > Breast